Informed Prostate Cancer Patient Support

Four of the 22 pesticides, were linked to an increased likelihood of death by prostate cancer. Pixavril – stock.adobe.com Weed killing chemical could be to blame for new crop of cancer Summary I'll provide guidance based on both medical and legal considerations: Medical Steps: 1. Immediate Medical Priority: - Focus first on your prostate cancer treatment plan with your doctors - Don't delay recommended medical treatments while pursuing other actions - Early detection and treatment are critical for prostate cancer outcomes - The article notes that prostate cancer has many treatment options including:   - Surgery   - Chemotherapy   - Immunotherapy   - Radiation   - Targeted drug therapy 2. Medical Documentation: - Document your Roundup exposure history in detail:   - How long you used it   - How frequently   - In what contexts (work, home gardening, etc.) - Share this exposure history with your medical team - Keep copies of all medical records an

Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction | Journal of Nuclear Medicine Andrei Gafita , Andrew Voter , Somya Shesadri , Avery Spitz , Catherine H. Marshall , Steven P. Rowe , Mark C. Markowski , Martin G. Pomper , A. Cahid Civelek , Michael A. Carducci , Samuel R. Denmeade , Jeffrey Young , Kenneth J. Pienta , Channing J. Paller and Lilja B. Solnes Journal of Nuclear Medicine November 2024, 65 (11) 1724-1730;   DOI: https://doi.org/10.2967/jnumed.124.267723   This figure summarizes the key findings from the study of Lu-PSMA therapy for advanced prostate cancer in a visual format. Let me break it down: The figure is divided into three main sections: 1. Left Section - Safety Profile & Efficacy: - Safety shows the percentage of side effects:   * Anemia (low red blood cells): 12%   * Thrombocytopenia (low platelets): 4%   * Neutropenia (low white blood ce

Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy | Journal of Nuclear Medicine jnm.snmjournals.org   Jeremie Calais, Michael J Morris, Ayse Tuba Kendi, Arash Rezazadeh Kalebasty, Ronald Tutrone, Michael J Anderson, Oliver Sartor Journal of Nuclear Medicine November 2024, 65 (11) 1666-1671; DOI: https://doi.org/10.2967/jnumed.124.268363   https://doi.org/10.2967/jnumed.124.268363     Research Article The State of the Art Summary Based on this comprehensive review paper from The Journal of Nuclear Medicine, here are the key points about best practices for PSMA-targeted radiopharmaceutical therapy (RPT) in metastatic castration-resistant prostate cancer (mCRPC): Key Adverse Event Management: 1. Most Common Adverse Events: - Fatigue (43.1% of patients) - Dry mouth (38.8%) - Nausea (35.3%) - Anemia (31.8%) 2. Management Strategies: - Fatigue: Can be managed with medications, transfusions, psychologica